

**CURRICULUM VITAE**

*January 2019*

**NAME:** Paul S. Jellinger, M.D., M.A.C.E.

**BIRTHPLACE:** New York City

**HOME ADDRESS:** 8647 Lewis River Road  
Delray Beach, Florida 33446

**PRESENT BUSINESS ADDRESS:**

The Center for Diabetes & Endocrine Care  
3107 Stirling Road,  
Suite 300  
Fort Lauderdale, Florida 33312  
(954)-963-7100

**PREVIOUS BUSINESS ADDRESS:**

1150 N. 35<sup>th</sup> Ave.  
Suite 590  
Hollywood, Florida 33021  
(954)-963-7100

**PRE-PROFESSIONAL EDUCATION:**

1. Horace Mann School  
New York, N.Y. 1956-1959
2. Hobart College  
Geneva, New York  
Bachelor of Arts (B.A.) 1959-1964
3. Graduate Division 1964-1965  
City College of New York  
Masters Program in Biology  
New York City, N.Y.

**PROFESSIONAL EDUCATION:**

1. Wayne State University  
School of Medicine  
Detroit, Michigan  
Doctor of Medicine (M.D.) 1965-1969

***POST-GRADUATE TRAINING:***

1. Fellowship - Endocrinology (N.I.H. Fellow)  
The Mount Sinai Hospital  
New York City, N.Y. 1973-1974
2. Fellowship - Endocrinology  
The Mount Sinai Hospital -- (Bronx V.A. Affiliation)  
New York, N.Y. 1972-1973
3. Second Year Residency - Internal Medicine  
The Mount Sinai Hospital  
New York City, N.Y. 1971-1972
4. First Year Residency - Internal Medicine  
Beth Israel Hospital  
New York City, N.Y. 1970-1971
5. Internship - Straight Medicine  
Beth Israel Hospital  
New York City, N.Y. 1969-1970

***SPECIALTY CERTIFICATION & LICENSURE:***

1. American Board of Internal Medicine  
Sub-Specialty Board in Endocrinology & Metabolism  
Certified, October 1975
2. American Board of Internal Medicine  
Certified, June 1972
3. State of Florida License #22389  
Issued June, 1974
4. New York State License #106101  
Issued June, 1970
5. Diplomate,  
National Board of Medical Examiners – 1970

***ACADEMIC APPOINTMENTS:***

Professor of Clinical Medicine  
University of Miami  
Miller School of Medicine  
Division of Endocrinology, Diabetes and Metabolism  
Miami, Florida  
2010-

Voluntary Professor of Medicine  
University of Miami School of Medicine  
Miami, Florida

Clinical Professor  
Department of Medicine (Endocrinology)  
University of Miami School of Medicine  
Miami, Florida

Clinical Associate Professor  
Department of Medicine (Endocrinology)  
University of Miami School of Medicine  
Miami, Florida

Clinical Assistant Professor  
Department of Medicine (Endocrinology)  
University of Miami School of Medicine  
Miami, Florida

Director, Endocrine & Diabetes Clinic  
Jackson Memorial Hospital  
University of Miami School of Medicine  
Miami, Florida

Consulting Physician in Medicine (Endocrinology)  
V.A. Hospital  
Miami, Florida

Clinical Instructor  
Department of Medicine (Endocrinology)  
University of Miami School of Medicine  
Miami, Florida

Assistant  
Department of Medicine  
The Mt. Sinai School of Medicine  
New York City, N.Y.

***HOSPITAL APPOINTMENTS:***

1. Chief, Section of Endocrinology  
Memorial Regional Hospital -- Hollywood, FL 1993-1996
2. Senior Attending Staff  
Memorial Regional Hospital—Hollywood, FL 1974-
3. Attending Staff  
Hollywood Medical Center—Hollywood, FL 1974-1998
4. Attending Staff  
Jackson Memorial Hospital  
University of Miami School of Medicine—Miami, FL 1975-1982
5. Director, Endocrine & Diabetes Clinic  
Jackson Memorial Hospital  
University of Miami School of Medicine—Miami, FL 1975-1976
6. Consulting Staff  
Biscayne Medical Center—Miami, FL 1975-1976

***PUBLICATIONS:***

1. AACE/ACE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM AND EXECUTIVE SUMMARY 2019. TASK FORCE, **WRITING COMMITTEE**  
*Endocr Pract.* 2019;25:69-100
2. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE CLINICAL PRACTICE GUIDELINES.  
*Diabetes Spectrum* 2018; 31(3) 234-245.  
*Jellinger, Paul S.*
3. *EDITORIAL:* AMERICAN COLLEGE OF PHYSICIANS DIABETES GUIDELINES ATTEMPT TO TURN BACK THE CLOCK, CONFLATING GOOD HBA1C WITH HYPOGLYCEMIA  
*Bloomgarden Z, Einhorn D, Handelsman Y, Misra A, Zonsein, J, Grunberger G, Jellinger P, Garber A*  
*Journal of Diabetes Vol. 10, Issue 8 April 14 2018*

4. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND THE AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY  
TASK FORCE, **WRITING COMMITTEE**  
*Endocrine Practice Vol. 24 No 1 January 2018 p.91-110*
5. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2017 GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE  
**CHAIR, WRITING COMMITTEE**  
*Jellinger P et al. Endocr Practice 2017;23(4):470-497.*
6. PCSK9 INHIBITOR ACCESS BARRIERS - ISSUES AND RECOMMENDATIONS: IMPROVING THE ACCESS PROCESS FOR PATIENTS, CLINICIANS AND PAYERS  
*Baum S, Toth P, Underberg J, Jellinger P, Ross J, Wilemon K  
Clinical Cardiology: 2017; 1-13 DOI: 10.1002/clc.22713*
7. INITIATING INJECTABLE TREATMENT FOR TYPE 2 DIABETES: FOCUS ON GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS  
*Jellinger PS, Consultant, May 2017; 57(5): 266-277*
8. OBVIATING MUCH OF THE NEED FOR INSULIN THERAPY IN TYPE 2 DIABETES MELLITUS: A RE-ASSESSMENT OF INSULIN THERAPY'S SAFETY PROFILE  
*Stanley S. Schwartz, Paul S. Jellinger & Mary E. Herman (May 2016):  
Postgraduate Medicine, DOI: 10.1080/00325481.2016.1191955*
9. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2016 EXECUTIVE SUMMARY  
TASK FORCE, **WRITING COMMITTEE**  
*Endocrine Practice Vol 22 No. 1 January 2016 p 84-113*
10. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR A DIABETES MELLITUS COMPREHENSIVE CARE PLAN, **TASK FORCE**  
*Endocr Practice Vol 21 No. 4 April 2015 p1-87*
11. TREATMENT OF DIABETES MELLITUS: THE URGENT NEED FOR MULTIFACTORIAL INTERVENTIONS  
Hennekens CH, Pfeffer MA, Newcomer J, Jellinger PS, Garber, A  
*American Journal of Managed Care, Vol 20, No 5 May 2014 p357-359.  
Commentary.*
12. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM 2013, **TASK FORCE**  
*Endocr Practice Vol 19, Number 2 March/April 2013 p 327-336.*

13. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS' GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF ATHEROSCLEROSIS: AACE LIPID AND ATHEROSCLEROSIS GUIDELINES.  
**CHAIR, AACE TASK FORCE FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF ATHEROSCLEROSIS: AACE LIPID AND ATHEROSCLEROSIS GUIDELINES**  
*Endocr Practice Vol 18 (Suppl 1) March/April 2012 p 1-78.*
14. ORAL PHARMACOLOGIC TREATMENT OF TYPE 2 DIABETES MELLITUS (INTERNISTS AND PRIMARY CARE PHYSICIANS SHOULD BECOME FAMILIAR WITH ALGORITHMS DEVELOPED BY PHYSICIANS WHO SPECIALIZE IN MANAGEMENT OF PATIENTS WITH DIABETES).  
*(Letter to the Editor), Rodbard HW, Jellinger PS, Annals of Internal Medicine 2012 Jul 3;157(1): p75-6.*
15. A CRITIQUE OF THE 2012 ADA/EASD POSITION STATEMENT  
*(Letter) Rodbard HW, Jellinger PS, Diabetologia 2012; 55 (10): p2850-2852. e-pub*
16. COMMENT ON: INZUCCHI ET AL. MANAGEMENT OF HYPERGLYCEMIA IN TYPE 2 DIABETES: A PATIENT-CENTERED APPROACH. POSITION STATEMENT OF THE AMERICAN DIABETES ASSOCIATION (ADA) AND THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD) (POSITION STATEMENT).  
*Rodbard HW, Jellinger PS, Diabetes Care 2012; 35: p1364–1379 (Letter to the Editor).*
17. PHYSICIANS' PRESCRIBING PATTERNS FOR PATIENTS WITH DIABETES ARE CHANGING FOR THE BETTER. (E-PUB)  
*Rodbard HW, Jellinger PS, Am J Med. 2012 Nov; 125(11): p11-2. (Commentary)*
18. OVERCOMING OBSTACLES IN RISK FACTOR MANAGEMENT IN TYPE 2 DIABETES MELLITUS  
*Handelsman Y, Jellinger, P The Journal of Clinical Hypertension Vol 13 | No 8 August 2011 p 613-620*
19. FOCUS ON INCRETIN-BASED THERAPIES: TARGETING THE CORE DEFECTS OF TYPE 2 DIABETES,  
*Jellinger PS Postgraduate Medicine, Volume 123, Issue 1, January 2011, p 53-65.*
20. THE POTENTIAL ROLE OF COLESEVELAM IN THE MANAGEMENT OF PRE-DIABETES AND TYPE 2 DIABETES MELLITUS  
*Levy P, Jellinger P Postgraduate Medicine, Volume 122, Issue 3, Suppl 1, May 2010 p 1-8.*

21. ADDING NONINSULIN ANTIDIABETIC DRUGS TO METFORMIN THERAPY FOR TYPE 2 DIABETES  
*Rodbard HW, Jellinger PS, JAMA 2010 Jul 28;304(4):405-6; author reply 406-7*
22. STATEMENT BY AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS (AACE) / AMERICAN COLLEGE OF ENDOCRINOLOGY (ACE) CONSENSUS PANEL ON TYPE 2 DIABETES MELLITUS: AN ALGORITHM FOR GLYCEMIC CONTROL  
**CO-CHAIR, ACE/AACE DIABETES ALGORITHM CONSENSUS PANEL**  
*Endocr Practice Vol 15 No. 6 September/October 2009, p 540-559.*
23. AMERICAN COLLEGE OF ENDOCRINOLOGY/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS PRE-DIABETES CONSENSUS STATEMENT  
*Endocr Practice 2008;14 No. 7 Vol 14 No. 7 October 2008, p 933-943.*
24. POSTPRANDIAL DYSMETABOLISM: THE MISSING LINK BETWEEN DIABETES AND CARDIOVASCULAR EVENTS?  
*Endocrine Practice, 2008, Vol 14, No.1, January/February 2008, p. 112-124.*
25. METABOLIC CONSEQUENCES OF HYPERGLYCEMIA AND INSULIN RESISTANCE  
*Clin Cornerstone 2007; 8 Suppl 7: p.30-42*
26. ACE/AACE DIABETES ROADMAPS TO ACHIEVE GLYCEMIC GOALS:  
**CO-CHAIR, ACE/AACE ROADMAP TASK FORCE**  
*Endocrine Practice, 2007, Vol. 13, No.3 May/June 2007, p.260- 268.*
27. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS (AACE) DIABETES MELLITUS CLINICAL PRACTICE GUIDELINES TASK FORCE  
*Endocrine Practice, Vol. 13, (Suppl 1) May/June 2007*
28. ACE/AACE CONSENSUS CONFERENCE ON THE IMPLEMENTATION OF OUTPATIENT MANAGEMENT OF DIABETES MELLITUS: CONSENSUS CONFERENCE RECOMMENDATIONS  
*Endocrine Practice, Vol. 12, No. 1 Jan/Feb 2006, p. 6-12*
29. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS POSITION STATEMENT ON METABOLIC AND CARDIOVASCULAR CONSEQUENCES OF POLYCYSTIC OVARY SYNDROME  
*Endocrine Practice, Vol. 11, No. 2 Mar/Apr 2005 p. 125-134*

30. ACQUIRED HYPOTHYROIDISM AFTER SWITCHING FROM THYROID USP TO LEVOTHYROXINE  
*Clin Cornerstone* 2005;7 Suppl 2: S22-4
31. AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON INSULIN RESISTANCE SYNDROME  
*Endocrine Practice* Vol. 9 No. 3, May/June 2003 p. 241-251
32. EMERGING CONCEPTS IN MANAGEMENT OF THE INSULIN RESISTANCE SYNDROME  
*Endocrine Practice*, Vol. 9, Supplement 2, Sept/Oct. 2003, p.105-112
33. AMERICAN COLLEGE OF ENDOCRINOLOGY CONSENSUS STATEMENT ON GUIDELINES FOR GLYCEMIC CONTROL  
*Endocrine Practice*, Vol. 8, Supplement 1, Jan/Feb 2002, p.5-11
34. RECOGNIZING CARDIOVASCULAR RISK IN PATIENTS WITH DIABETES  
*The American Journal of Cardiology*  
*Continuing Education Series Monograph*, 2002, Editor
35. POSTPRANDIAL HYPERGLYCEMIA AND CARDIOVASCULAR RISK  
*The American Journal of Cardiology*  
*Continuing Education Series Monograph*, 2002, p.11-15
36. A.A.C.E. MEDICAL GUIDELINES FOR THE TREATMENT OF DYSLIPIDEMIA IN THE PREVENTION OF ATHEROGENESIS, **CHAIR**, TASK FORCE  
American Association of Clinical Endocrinologists,  
*Endocrine Practice*, Vol. 6, p. 162 –213, 2000
37. A.A.C.E. GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS, **TASK FORCE**  
American Association of Clinical Endocrinologists, Revised, 2000
38. A.A.C.E. GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS, **TASK FORCE**  
American Association of Clinical Endocrinologists, 1994
39. A.A.C.E. CLINICAL PRACTICE GUIDELINES FOR THE EVALUATION AND TREATMENT OF HYPERTHYROIDISM AND HYPOTHYROIDISM, **TASK FORCE**  
American Association of Clinical Endocrinologists, 1994.
40. LH RESPONSIVENESS IN SUBJECTS WITH SECONDARY AMENORRHEA: Clinical Research (abstra.), Vol. XXIII, No. 3, April, 1975





**HONORS:**

1. *Yank D. Coble, Jr., MD, Distinguished Service Award*  
**American College of Endocrinology**, May 2017
2. President, **American College of Endocrinology**, 2003 –2004
3. Master, **American College of Endocrinology (MACE)**, May 2004
  
4. President, **American Association of Clinical Endocrinologists**, 2000-2001
  
5. *Best Doctors in the United States, 2011-2018, yearly, as chosen by peers.*
6. *Best Doctors in the United States, 2010-2011, as chosen by peers.*
7. *Best Doctors in the United States, 2009-2010, as chosen by peers.*
8. *Best Doctors in the United States, 2008-2009, as chosen by peers.*
9. *Best Doctors in the United States, 2007-2008, as chosen by peers.*
10. *Best Doctors in the United States, 2006-2007, as chosen by peers.*
11. *Best Doctors in the United States, 2005-2006, as chosen by peers.*
12. *Best Doctors in the United States, 2004-2005, as chosen by peers.*
13. *Best Doctors in the United States, 2003-2004, as chosen by peers.*
14. *Best Doctors in the United States, 2001-2002, as chosen by peers.*
15. *Best Doctors in the United States, 2000, as chosen by peers*
16. *Best Doctors in Florida, 2000, as chosen by peers.*
17. *Best Doctors in the Southeast United States, 1999, as chosen by peers.*
18. *Best Doctors in South Florida, 1998, 2000, as chosen by peers.*
19. Fellow, American College of Endocrinology,  
First Convocation and Assembly, May, 1994.

**ORGANIZATIONS:**

1. Broward County Medical Association
2. Florida Medical Association
3. American Medical Association
4. American Diabetes Association
5. The Endocrine Society
6. American Association of Clinical Endocrinologists
7. South Florida Endocrine Association.
8. The Florida Endocrine Society
9. American Heart Association

**POSITIONS HELD:**

1. Medical Editor in Chief  
*Clinical Endocrinology News*, Elsevier Publications  
January 2006 -2013
2. President  
American College of Endocrinology  
May 2004 – May 2005
3. President-Elect  
American College of Endocrinology  
May 2003 – May 2004
4. President  
American Association of Clinical Endocrinologists  
May 2000 - May 2001
6. President Elect  
American Association of Clinical Endocrinologist  
May 1999 – May 2000
7. Vice-President  
American Association of Clinical Endocrinologists  
May 1998 - May 1999
8. Treasurer  
American Association of Clinical Endocrinologists  
May 1997 - May 1998
9. Secretary  
American Association of Clinical Endocrinologists  
May 1996 - May 1997
10. Program Co-Chairman, Annual Meeting  
American Association of Clinical Endocrinologists  
San Diego, 1999

11. Executive Committee  
American Association of Clinical Endocrinologists  
May, 1996 -
12. Program Co-Chairman, Annual Meeting  
American Association of Clinical Endocrinologists
13. Chairman, Internet Committee  
American Association of Clinical Endocrinologists  
1998 -
14. Program Chairman AACE Clinical Symposium  
Dyslipidemia, Diabetes & Obesity  
Montreal, August 1997
15. Program Chairman, American Diabetes Association Council  
on Endocrinology; Diabetes and Metabolism,  
"The DCCT: One Year Later." New Orleans 1993-1994
16. Secretary, American Diabetes Association Council on  
Endocrinology; Diabetes and Metabolism 1992-1993
17. Chairman, State Affiliate Organization Committee,  
American Association of Clinical Endocrinologists 1994-
18. Chairman, Clinical MiniFellowship Program Committee  
American Association of Clinical Endocrinologists 1994-
19. Board of Directors  
American Association of Clinical Endocrinologists 1992-
20. Chairman, Membership Committee  
American Association of Clinical Endocrinologists 1991- 1999
21. Member, Committee on Clinical Practice and Technology  
American Association of Clinical Endocrinologists 1991-94
22. Founding Member, Steering Committee  
American Association of Clinical Endocrinologists 1991
23. Director, Diabetes Care Unit  
Hollywood Medical Center 1987-1992
24. Founder  
South Florida Endocrine Association 1988
25. President  
Florida Endocrine Society 1986-1988
26. President-Elect  
Florida Endocrine Society 1984-1986

27. Secretary/Treasurer  
Florida Endocrine Society 1982-1984
  
28. Director, Endocrine & Diabetes Clinic  
Jackson Memorial Hospital  
University of Miami School of Medicine—Miami, FL 1975-1977

***PROFESSIONAL SOCIETIES:***

1. Master, American College of Endocrinology (M.A.C.E.)
2. The Endocrine Society (elected) 1985
3. South Florida Endocrine Association-Founder, 1988
4. The Florida Endocrine Society
5. American Association of Clinical Endocrinologists
6. American Diabetes Association
7. American Heart Association
8. American Heart Association Council on Arteriosclerosis
9. Fellow, American College of Endocrinology (F.A.C.E.)

***LOCAL REGIONAL & NATIONAL PRESENTATIONS:***

Medical Grand Rounds Presentations  
Memorial Hospital, Hollywood, FL 1974-1994

***TOPICS***

Thyroid Function Tests: An Update  
Hypoglycemia  
The Thyroid Nodule  
Pituitary Disease: New Concepts  
Hypercalcemia  
Paget's Disease  
Osteoporosis  
Diabetes Mellitus - 1988 - An Update  
Hyperlipidemia - NCME Video Tape-Moderator  
Type II Diabetes, New Concepts-Moderator  
Diabetes Complications and Control Trial:  
A Landmark Study, November, 1993

1. Juvenile Diabetes Research Foundation, Miami, FL 1975  
Topic: Concepts in Diabetic Control
2. Nursing Education, Memorial Regional Hospital—Hollywood, FL 1975-1979,  
(Yearly)  
Topic: Endocrine Emergencies
3. Clinical Radioassay Society, Annual Meeting, Panel Moderator, 1980  
Topic: Thyroid Nodules and Neoplasms
4. Florida Osteopathic Medical Association, Annual Meeting, March 1990  
Topic: Thyroid Nodules and Neoplasms

5. American Society of Medical Technologists, Annual Meeting,  
Florida Division, 1981  
Topic: Pituitary Disease: New Concepts & Testing
6. Symposium, Memorial Regional Hospital—Hollywood, FL  
Topic: The Dynamics of Calcium Metabolism with Drs. L. Deftos and A.  
Norman
7. Florida Endocrine Society, Program Chairman & Moderator, May 1981  
Topic: Thyroid Nodule & Neoplasm
8. University of Miami, Sponsored Course in Endocrinology for the  
Primary Care Physician, October 1981  
Topic: Thyroid Nodule & Neoplasm
9. Diabetes Mellitus, Type II - New Concepts  
Roerig Speaker's Board, Pembroke Pines Hospital, March 1989
10. The Significance of HDL Cholesterol in the Hyperlipidemic State  
Parke Davis Speaker's Bureau, North Broward Regional Hospital,  
Pompano Beach, FL January 1990
11. Hyperlipidemia 1990: An Update - The Role of HDL Cholesterol  
Parke Davis Speaker's Bureau, West Palm Beach, FL June 1990
12. Update on Hyperlipidemia - 1990 - The Role of HDL Cholesterol  
Parke Davis Speaker's Bureau, Jacksonville, FL April 1990
13. Diseases of the Pituitary Gland  
Lecturer in Endocrinology, annually, (Second Year Medical Students)  
Southeastern University of Health Sciences, N. Miami Beach, FL July 1990
14. The Significance of HDL Cholesterol in the Hyperlipidemic State  
Parke Davis Speaker's Bureau, Orlando, FL February 1991
15. Comparative Pharmacology of Agents Affecting Hypercholesterolemia  
Merck, Sharp & Dohme Speaker's Bureau, Orlando, FL May 29, 1991
16. Comparative Pharmacology of Agents Affecting Hypercholesterolemia  
Merck, Sharp & Dohme Speaker's Bureau, Ft Lauderdale, FL March 1992
17. Update on Hyperlipidemia  
Merck, Sharp & Dohme Speaker's Bureau, Ft Lauderdale, FL Nov. 1992
18. Florida Endocrine Society Annual Meeting 1976 - present  
Case presentations and discussion
19. Diabetic Neuropathy: Clinical Considerations  
American Association of Clinical Endocrinologists, Annual Meeting  
San Francisco, CA April, 1993 - Workshop Leader
20. Diabetes Complications and Control Trial  
Memorial Regional Hospital—Hollywood, FL November 1993
21. Diabetes Complications and Control Trial - A Landmark Study  
Pratt Pharmaceutical Speaker's Bureau, Hollywood, FL February 1994
22. Advanced Insulin Infusion Pump Symposium  
MiniMed Corporation, Ft Lauderdale, FL March 5<sup>th</sup> & 6<sup>th</sup>, 1994  
Symposium Moderator & Workshop Leader

23. Dyslipidemia: When to Treat, Who to Treat & How to Treat  
American Association of Clinical Endocrinologists, Annual Meeting  
New Orleans, Louisiana, April 1994, Workshop Moderator and Discussant
24. Diabetes Complications and Control Trial: One Year Later  
Council on Endocrinology, Diabetes and Metabolism, American Diabetes  
Association Annual Meeting, Program Chairman and Moderator  
New Orleans, Louisiana, June 1994
25. Hyperlipidemia: Treatment and Regression  
Merck, Sharp & Dohme Speaker's Bureau, Ft Lauderdale, FL June 1994
26. Diabetes Complications and Control Trial Results; Implications for Patients with  
Type II Diabetes, Sponsored by Novo Nordisk and Boehringer Mannheim Corp  
Holy Cross Hospital, Department of Medicine, Ft Lauderdale, FL July 1994
27. Atherosclerosis for the Endocrinologist: Lipids, Diabetes and Vascular Medicine  
American Association of Clinical Endocrinologists Regional Symposium  
Program Chairman and Discussant, Palm Beach, FL December 1994
28. A Practical Approach to the Treatment of Diabetic Neuropathy  
American Association of Clinical Endocrinologists Regional Symposium  
Keystone, CO January 1995
29. Method of Implementing Diabetes Intensive Self-Management in NIDDM  
American Association of Clinical Endocrinologists  
Regional Symposium, Keystone, CO January 1995
30. Dyslipidemia: Case Studies  
American Association of Clinical Endocrinologists, Annual Meeting, Workshop  
Leader, Chicago, IL April 1995
31. Diabetes Grand Rounds: Case Reviews  
American Association of Clinical Endocrinologists, Annual Meeting  
Moderator & Discussant, Chicago, IL April 1995
32. NIDDM: Newer Concepts in Diabetic Management  
92<sup>nd</sup> Annual Florida Osteopathic Medical Convention  
Doral Ocean Beach Resort, Miami Beach, FL March 1995
33. New Developments in the Treatment of Type II Diabetes Mellitus  
Department of Internal Medicine, North Broward Medical Center  
Pompano Beach, FL March 1995
34. New Concepts in Treatment of Type II Diabetes  
American Association of Diabetes Educators, South Florida Chapter  
Holy Cross Hospital, Ft Lauderdale, FL April 11, 1995
35. Lipid Disorders and Cardiovascular Disease in Women  
Cleveland Clinic Symposium: Women's Health Issues, Ft Lauderdale, FL June 1995
36. New Developments in the Treatment of Type II Diabetes  
Memorial Regional/Pembroke Pines Hospital Medical Staff,  
Pembroke Pines, FL June 1995.
37. New Developments in the Treatment of Type II Diabetes  
Coral Springs Hospital, Department of Internal Medicine/FP  
Coral Springs, FL June 1995

38. Case Studies in Intensive Self Management of Diabetes: Risk Factor Management  
 AACE Symposium -- Keystone, CO January 1996
39. Lipid Disease - Program Moderator  
 AACE Annual Meeting -- Seattle, WA May 1996
40. Lipid Disease - Workshop Leader  
 AACE Annual Meeting -- Seattle, WA May 1996

***PREVIOUS RESEARCH PROJECTS:***

1. An Open Label Study of Fluvastatin in the Treatment of Patients with Hypercholesterolemia In Clinical Practice Settings  
 Sandoz Pharmaceuticals -- Principal Investigator
2. A Randomized, Multicenter Long-Term Follow-up Trial in Patients with Diabetic Foot Ulcers  
 Telios Pharmaceuticals Inc. -- Co-Investigator
3. Efficacy and Safety of Domperidone in Patients with Diabetic Gastroparesis  
 Janssen Research -- Principal Investigator
4. Treatment of Infected Diabetic Foot Ulcers  
 Magainin Pharmaceuticals, Inc. -- Co-Investigator
5. An Insulin Sensitizer in the treatment of NIDDM Patients Requiring Insulin, Phase I & Phase II  
 Parke-Davis Pharmaceutical Research -- Principal Investigator
6. Protect (Precose) Study in NIDDM  
 Bayer Pharmaceuticals -- Co-Investigator
7. Feminine Hygiene Study  
 International Pharmaceutical Research -- Sub-Investigator
8. Human X-14 Insulin Study Type I DM  
 Novo Nordisk Pharmaceuticals -- Principal Investigator
9. IGF-I in Type I DM  
 Genentech, Inc. -- Sub-Investigator
10. Intravitreal injection of Hyaluronidase in Vitreal Hemorrhage  
 Advanced Corneal Systems, Inc. -- Sub-Investigator
11. Type II DM with Renal Impairment using Voglibose  
 Takeda America, Inc. -- Sub-Investigator
12. Open-Label Pramlintide in the Treatment in Type I DM  
 Amylin Pharmaceuticals -- Principal Investigator
13. Postmenopausal Women with Established Osteoporosis-Related Vertebral Deformities  
 Proctor & Gamble -- Principal Investigator
14. Topical Nitroglycerin Cream for the Treatment of Erectile Dysfunction  
 International Medcial Innovations, Inc. -- Sub-Investigator





15. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel 9 Week Study of Omapatrilat in the Treatment of Mild to Moderate Hypertension  
Bristol-Myers Squibb -- Sub-Investigator
16. A Randomized, Placebo-Controlled, Parallel-Group Study of CS-866 with Long- Term Safety Evaluation in Patients with Essential Hypertension  
Sankyo USA -- Sub-Investigator
17. Evaluating Metformin HCl Vs. Glyburide in Subjects With Type II Diabetes Mellitus Controlled On Sulfonylurea Monotherapy  
Bristol-Myers Squibb -- Principal Investigator
18. An Open-Label, Community-Based Clinical Practice Study of Niaspan in Patients with Hyperlipidemia  
Kos Pharmaceuticals -- Sub-Investigator
19. A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Prospectively Evaluate the Post-Prandial Glucose Excursion, the Daytime Glucose and Insulin Profiles, Safety, and Tolerability of a Fixed Dose of SDZ DJN 608, A Forced Titrated Dose of Glyburide, and Placebo in Subjects with NIDDM on Diet Alone  
Novartis Pharmaceuticals -- Sub-Investigator
20. A Comparison of Echocardiographic Findings in Patients Treated with Redux  
Interneuron Pharmaceuticals, Inc.—Sub-Investigator
21. TRICOR U.S. Multicenter Physician Experience Trial  
Abbott Laboratories Inc.—Principal Investigator
22. Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Effects of Pramlintide on Glycemic Control as Determined by Glycated Hemoglobin in Patients with Type II Diabetes Mellitus  
Amylin Pharmaceuticals -- Sub-Investigator
23. Open-Label Long-Term Study of the Antihypertensive Activity and Safety of Omapatrilat, a Dual Metalloprotease Inhibitor, in the Treatment of Hypertension  
Bristol-Myers Squibb -- Sub-Investigator
24. Reach-Rezulin Achieves Glycemic Control; A Multicenter, 24-week, Open-Label, Dose-Escalation Trial of Rezulin in Combination with Insulin or Sulfonylurea in Type II Diabetes Mellitus Patients  
Parke-Davis -- Sub-Investigator
25. Safety and Efficacy of Fixed Combination Metformin/Glyburide Products as First Line Therapy in Patients with Type II Diabetes Mellitus who Have Inadequate Glycemic Control with Diet and Exercise  
Bristol-Myers Squibb -- Principal Investigator
26. A Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Effects of Pramlintide on Glycemic Control as Determined by Glycated Hemoglobin in Patients with Type I Diabetes Mellitus  
Amylin Pharmaceuticals -- Sub-Investigator
27. A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, 18 Month Study to Assess the Safety and Efficacy of Meridia 20 mg  
Knoll Pharmaceuticals -- Co-Investigator

28. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of the Efficacy and Safety of Metformin Hydrochloride for the Treatment of Adolescents with Type 2 Diabetes Mellitus  
Bristol-Myers Squibb -- Sub-Investigator
29. Efficacy and Safety of Inhaled Human Insulin Compared to Subcutaneous Human Insulin in an Intensive Insulin Regimen for Subjects with Type 1 DM  
Pfizer, Inc.—Sub-Investigator
30. Efficacy and Safety of Inhaled Human Insulin Therapy in Subjects with Type 2 DM Not Well-Controlled with Combination Oral Agents  
Pfizer, Inc. -- Sub-Investigator
31. Double- Blind, Placebo- Controlled, Four-Week Study of the Safety and Efficacy of CP-386,296 in Subjects with Type 2 DM Pfizer  
Inc. – Sub-Investigator
32. Glipizide GITZ Study in Usual Care Setting  
Pfizer, Inc – Sub-Investigator
33. The Effect of PNU-182716 on HbA1c Levels in Type 2 Diabetic Patients, a Double-Blind, Placebo-Controlled, Randomized, Multicenter Dose-Finding and Frequency Study  
Pharmacia & UpJohn – Sub-Investigator
34. A Randomized, Double-Blind, Parallel- Group, Pilot Study of 3 Months Treatment with Oral GI262570 7.5 mg Once Daily, Pioglitazone 45 mg Once Daily, and Rosiglitazone 4 mg Twice Daily in Subjects with Type 2 DM  
Glaxo Wellcome—Sub-Investigator
35. Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Noninsulin Dependent Diabetes Mellitus and Nephropathy  
Merck & Company -- Co- Investigator
36. Efficacy and Safety of Inhaled Human Insulin Therapy in Subjects with Type 2 Diabetes Mellitus not Optimally Controlled with Diet and Exercise  
Pfizer, Inc.—Sub-Investigator
37. Insulin Lispro Low Mixture Plus Metformin Compared to NPH Insulin Plus Metformin in Subjects with Type 2 DM  
Eli Lilly and Company – Sub-Investigator

***CURRENT RESEARCH PROJECTS :***

1. A Triple-Blind, Parallel Study to Investigate the Effect of Losartan versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients with Left Ventricular Hypertrophy  
Merck & Company -- Co- Investigator
2. The Hypopituitary Control and Complications Study with Humatrope  
Eli Lilly and Company -- Sub-Investigator

3. Long Term Safety of Inhaled Insulin in Subjects with Type 1 or Type 2 DM  
Pfizer, Inc -- Sub-Investigator
4. Double-Blind, Randomized Study of the Safety and Efficacy of a Combination of Insulin and 30 mg of Actos vs. a Combination of Insulin and 45 mg of Actos in the Treatment Type 2 DM  
Takeda America -- Sub- Investigator
5. A Randomized, Double-Blind, Parallel- Group, Placebo-Controlled Clinical Evaluation of GI262570 Sodium Tablets as a Monotherapy for 26 weeks in Subjects with Type 2 DM  
Glaxo Wellcome—Sub-Investigator
6. A Randomized, Double-Blind, Parallel- Group, Clinical Evaluation of GI262570 Sodium Tablets in Combination with Metformin for 26 weeks in Subjects with Type 2 DM  
Glaxo Wellcome—Sub-Investigator
7. A Double-Blind, Randomized Comparison Study of the Safety and Efficacy of the Addition of Pioglitazone or Placebo in Reducing or Eliminating Insulin Requirement in Subjects Controlled on Insulin and Metformin Who Have Previously Failed Combination Oral Therapy  
Takeda Pharmaceuticals America—Sub-Investigator
8. A Double-Blind, Randomized Comparison Study of the Long Term (2 yr) Safety and Efficacy of Pioglitazone or Glyburide in Subjects with Type 2 DM Naïve to Pharmacologic Therapy  
Takeda Pharmaceuticals America—Sub-Investigator
9. Randomized, Multicenter, Double-Blind, Placebo-Controlled trial with Two Parallel Groups to Measure the Efficacy of 12 Weeks Treatment with 120 mg of Nateglinide vs Placebo in Treatment of Naïve Older Seniors with Type 2 DM  
Novartis Pharmaceuticals -- Sub-Investigator
10. Multicenter, Randomized, Double-Blind Trial Comparing the Safety and Efficacy of Metformin/Glyburide to Pioglitazone in Patients with Type 2 DM  
Bristol-Myers Squibb -- Sub-Investigator
11. Double-Blind Randomized Study to Evaluate the Effects of Fixed Combination Metformin/Glipizide in Patients with Type 2 DM  
Bristol-Myers Squibb – Sub-Investigator
12. Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effect on Glucose Control of AC2993 in Subjects with Type 2 DM  
Amylin Pharmaceuticals -- Sub-Investigator
13. 18 Month, Double-Blind Phase 3 Trial with a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone in Women with Postmenopausal Osteoporosis  
NPS Allelix Corporation – Sub-Investigator
14. Randomized, Open Label, Crossover Trial in Insulin Requiring Diabetic Patients, Comparing the Injections with BiaSp 30/MS216 Disposable Pen Device and Injections with BiaSp 30/vial and Syringe  
Novo Nordisk Pharmaceuticals, Inc. – Sub-Investigator

15. NNC61-0029 in Type 2 DM Hypertriglyceridemic Patients: Double-Blind, Parallel, Placebo-Controlled with an Open Pioglitazone Arm  
Novo Nordisk Pharmaceuticals, Inc. – Sub-Investigator
16. Randomized, Double-Blind, Parallel-Group, Dose-Ranging Study to Assess the Efficacy and Safety of GI262570 Administered as a Daily Dose in Subjects with Type 2 DM  
Glaxo Wellcome, Inc. – Sub-Investigator
17. Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of Treatment with Simvastatin in TZD Treated Type 2 DM Patients  
Merck & Co., Inc. – Sub-Investigator
18. Efficacy, Dose-Ranging and Safety for RWJ-241947 in Type 2 DM Patients Inadequately Controlled on Diet, Metformin, or Sulfonylurea: A Phase 2b Trial  
RW Johnson PRI – Sub-Investigator